搜狐体育nba

二维码 扫一扫有欣喜

对于百克

About BaiKe

接洽咱们

CONTACT US

办事热线:
400-8845-777

在线征询: 专家在线

企业邮箱:

发卖收集: 点击征询

公司邮编:130012

企业官网:tssx.com.cn 公司地点:吉林省长春市高新手艺财产开辟区火把路1260号

荷兰Mucosis B.V.公司

以后地位:

荷兰Mucosis B.V.公司

宣布日期:2015-09-25 11:09:07   信息来历:首创   点击量:11662



Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is , an intranasal vaccine to prevent infection. Our vaccines are based on the patented and validated. This technology enables a more natural immune response as well as a broad base of protection as was seen in our proof-of-concept animal and human studies of our FluGEM® vaccine candidate.


The Mucosis Mimopath® technology is a plug- and play vaccine platform that addresses the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune system. This mechanism efficiently evokes immune responses that engage disease-causing pathogens at their port of entry, the mucosal layers of the body. Uniquely, our technology is built on particles that not only elicit a strong and robust systemic immune response, but also a strong local immune response in mucosal layers in the nose, airways, gut and other places in the body.


The core of the Mimopath® technology is the . The BLPs are safe and derived from food-grade bacteria. There are two modes of application of the BLPs. The first is an Add & Mix approach in which the immune stimulating properties of the BLPs are used to improve existing vaccines and to enable a mucosal route of administration. The second is a Bound approach in which the BLPs not only act as immunostimulant but also as a carrier for the subunit antigen(s). The binding of the antigens is achieved by a linker domain called that binds to the surface of the BLPs.


were used by our scientists and collaborators who demonstrated in animal models that Mimopath®-based vaccines are protective against live parasites (malaria) viruses (influenza, hepatitis B) and bacteria (Streptococcus pneumonia, Yersinia pestis). Mimopath®-based vaccines were shown to be effective both as injectable and mucosal formats and in addition, proved to be highly effective in stimulation of the neonatal immune system. This forms the basis for a broad application of this new and innovative vaccine technology.




Ramirez K , Ditamo Y, Rodriguez L, Picking WL, Roosmalen ML van, Leenhouts K, Pasetti MF. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol. 2010; 3:159–171.